Solid Organ Transplantation Self-Assessment Program (SOTSAP) (L259216)
ACPE Numbers: Various – see listing below Release Date: November 17, 2025 Expiration Dates: November 17, 2026 Activity Type: Application-based CE Credits: 16.5 contact hours (BPS and ACPE) Activity Fee: $88 (ASHP member); $132 (non-member)
Activity Overview
This course is intended for board-certified pharmacists in need of recertification credit and is designed based on the content outline developed by Board of Pharmacy Specialties (BPS). The course consists of 8 topics (see table below) and provides 16.5 contact hours of continuing pharmacy education and/or recertification credit.
Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.
These activities are part of the ACCP and ASHP professional development program for BCTXP recertification approved by the BPS.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.
The target audience for Solid Organ Transplant Self-Assessment Program (SOTSAP) 2025 and is board-certified and advanced level solid organ transplant clinical pharmacists.
Board-certified pharmacists are eligible to receive up to 16.5 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.
ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.
ACCP and ASHP are approved by BPS as a provider for the recertification of BCTXP.
Learning Activity
Passing Score
Credit Information
Chapter: Calcineurin Inhibitor Management and Minimization Strategies
80%
2.0 Contact Hours
BPS: BCTXP ACPE: 0217-9999-25-215-H01-P
Chapter: Immunosuppression Strategies in Special Transplants
Chapter: Calcineurin Inhibitor Management and Minimization Strategies ACPE: 0217-9999-25-215-H01-P
Convert an immediate-release tacrolimus regimen to extended-release tacrolimus on the basis of patient-specific factors.
Assess the risk-benefit of calcineurin inhibitor (CNI) minimization strategies in solid organ transplant recipients.
Develop a patient care plan for transition to an alternative immunosuppression regimen that minimizes CNI exposure.
Evaluate CYP3A5 genotype data to predict the tacrolimus metabolism phenotype.
Apply patient-specific pharmacogenetics to selecting a posttransplant tacrolimus regimen.
Chapter: Immunosuppressive Strategies in Special Transplants ACPE: 0217-9999-25-216-H01-P
Design a maintenance plan for immunosuppression for an intestinal transplant (ITx) recipient.
Distinguish patient scenarios that may warrant the use of adjunctive or alternative maintenance agents in an ITx recipient.
Apply evidence of allogenic islet cell maintenance immunosuppressive outcomes to patient scenarios.
Analyze maintenance immunosuppressive regimens for face, limb, and uterus transplant (UTx) recipients.
Convert maintenance immunosuppressive medications for face, limb, and UTx recipients to alternative or adjunctive agentson the basis of patient-specific factors.
Assess risk factors for developing posttransplant diabetes (PTD) in solid organ transplant (SOT) recipients.
Develop a patient care plan for managing PTD in SOT recipients.
Analyze the role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or sodium-glucose cotransporter-2 (SGLT2)inhibitors for managing PTD according to available evidence for their use in SOT recipients.
Assess risk factors for developing osteoporosis in SOT recipients.
Develop a patient care plan for managing osteoporosis after transplantation in SOT recipients.
Analyze the risk-benefit of modifying immunosuppressive regimens after transplantation to alleviate the risk of developingPTD and/or osteoporosis.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ACCP and ASHP require that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
Grants: Maya Campara (argenx research funding to University of Illinois Chicago)
Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:
Complete the attestation statement
Review all content
Complete and pass the assessments
Complete the evaluations
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
